Marie-Louise Trotman

TL;DR: In an unadjusted intention-to-treat analysis, cinacalcet did not significantly reduce the risk of death or major cardiovascular events in patients with moderate- to-severe secondary hyperparathyroidism who were undergoing dialysis.

TL;DR: The analyses presented herein suggest that the intervention may have an effect while subjects are receiving treatment, and additional analyses should be considered to assess the on‐treatment effect when substantial non‐adherence to study drug is expected or observed.

TL;DR: Treatment of secondary hyperparathyroidism with calcimimetic therapy may in fact reduce mortality among patients receiving maintenance dialysis, and this finding provides justification for a well-designed and adequately powered randomized trial to definitively address the question.

TL;DR: In this paper, the authors defined the frequency of fatal and nonfatal cardiovascular events attributable to atherosclerotic and nonatherosclerosis mechanisms, risk factors for these events, and the effects of cinacalcet, using adjudicated data collected during the EValuation of CINACALcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.

TL;DR: Based on this pooled analysis, anti-erenumab antibodies have a low occurrence rate, high reversion rate, and most importantly, no appreciable clinical impact on the efficacy or safety in erenumab-treated subjects.